Last reviewed · How we verify
NKX019
At a glance
| Generic name | NKX019 |
|---|---|
| Also known as | NKX019 infusion |
| Sponsor | Nkarta, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (PHASE1, PHASE2)
- A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) (PHASE1, PHASE2)
- A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus (PHASE1)
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NKX019 CI brief — competitive landscape report
- NKX019 updates RSS · CI watch RSS
- Nkarta, Inc. portfolio CI